The Lancet Gastroenterology & Hepatology - Colorectal cancer is the second most common cause of cancer death in men and women in the USA. Research has shown that colorectal cancer screening reduces associated incidence and mortality.

Regular testing is essential for good patient outcomes; approximately 90% of those diagnosed with early-stage colorectal cancer live for 5 years or more.

A group of American researchers pointed out the inconsistency of screening guidelines for patients older than 75 years, which could lead to over-screening or under-screening. They strongly suggest that colorectal cancer screening guidelines should be re-evaluated and revised to be evidence-based, objective, and consistent across organizations to provide tailored, appropriate care for all patients.

 

The subjective decision of cessation of colorectal cancer screening

 

Authors: Casey L Daniel, Danielle Keyes, Kelly Gilreath

The Lancet Gastroenterology & Hepatology, DOI: http://dx.doi.org/10.1016/S2468-1253(17)30254-6, October 2017